Holocene Advisors, LP Alnylam Pharmaceuticals, Inc. Transaction History

Holocene Advisors, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $106 Million - $136 Million	-579,381 Reduced 96.74%	19,547 $3.92 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $8.3 Million - $10.8 Million	-44,721 Reduced 6.95%	598,928 $142 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $89.2 Million - $149 Million	643,649 New	643,649 $129 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $9.73 Million - $13.3 Million	76,483 Added 10.58%	799,222 $131 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $9.81 Million - $12.9 Million	61,509 Added 9.3%	722,739 $123 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $18 Million - $22 Million	105,991 Added 19.09%	661,230 $125 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $71.4 Million - $98.2 Million	555,239 New	555,239 $94.1 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $8.79 Million - $14.7 Million	-117,988 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $8.37 Million - $10.4 Million	117,988 New	117,988 $9.49 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.